RISS 학술연구정보서비스

검색
다국어 입력

http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.

변환된 중국어를 복사하여 사용하시면 됩니다.

예시)
  • 中文 을 입력하시려면 zhongwen을 입력하시고 space를누르시면됩니다.
  • 北京 을 입력하시려면 beijing을 입력하시고 space를 누르시면 됩니다.
닫기
    인기검색어 순위 펼치기

    RISS 인기검색어

      KCI등재 SCI SCIE SCOPUS

      Inhalation Therapy of Calcitonin Relieves Osteoarthritis of the Knee

      한글로보기

      https://www.riss.kr/link?id=A104750882

      • 0

        상세조회
      • 0

        다운로드
      서지정보 열기
      • 내보내기
      • 내책장담기
      • 공유하기
      • 오류접수

      부가정보

      다국어 초록 (Multilingual Abstract)

      This study was conducted to determine if nasal salmon calcitonin has additional beneficial effects on clinical symptoms, serum NO, IL-1β, matrix metalloproteinase 3, urinary C-terminal telopeptide type II collagen (CTX-II) levels and MRI findings in knee osteoarthritis (OA) when used concomitantly with exercise therapy. Fifty female patients with knee OA were randomized into two groups. The first group (n = 30) received 200 IU/day nasal salmon calcitonin and a home exercise program; the second group (n = 20)received a home exercise program for 6 months. Compared with baseline, while significant improvements were observed in visual analogue scale (VAS), WOMAC pain, physical function scores, 20-m walking time (P < 0.001) and WOMAC stiffness score (P = 0.041) in the first group, walking and resting VAS, and WOMAC physical function scores were improved (P = 0.029) in the second group after treatment. Significantly increased levels of serum NO and urinary CTX-II (P < 0.001) and significant improvements in the area of medial femoral condyle (P < 0.05) were noted only in the first group. There were significant differences in VAS activation values (P = 0.032) and NO levels (P < 0.001) in the favor of the first group. In conclusion, nasal salmon calcitonin may have possible chondroprotective effects besides its known effects on symptoms in patients with knee OA.
      번역하기

      This study was conducted to determine if nasal salmon calcitonin has additional beneficial effects on clinical symptoms, serum NO, IL-1β, matrix metalloproteinase 3, urinary C-terminal telopeptide type II collagen (CTX-II) levels and MRI findings in ...

      This study was conducted to determine if nasal salmon calcitonin has additional beneficial effects on clinical symptoms, serum NO, IL-1β, matrix metalloproteinase 3, urinary C-terminal telopeptide type II collagen (CTX-II) levels and MRI findings in knee osteoarthritis (OA) when used concomitantly with exercise therapy. Fifty female patients with knee OA were randomized into two groups. The first group (n = 30) received 200 IU/day nasal salmon calcitonin and a home exercise program; the second group (n = 20)received a home exercise program for 6 months. Compared with baseline, while significant improvements were observed in visual analogue scale (VAS), WOMAC pain, physical function scores, 20-m walking time (P < 0.001) and WOMAC stiffness score (P = 0.041) in the first group, walking and resting VAS, and WOMAC physical function scores were improved (P = 0.029) in the second group after treatment. Significantly increased levels of serum NO and urinary CTX-II (P < 0.001) and significant improvements in the area of medial femoral condyle (P < 0.05) were noted only in the first group. There were significant differences in VAS activation values (P = 0.032) and NO levels (P < 0.001) in the favor of the first group. In conclusion, nasal salmon calcitonin may have possible chondroprotective effects besides its known effects on symptoms in patients with knee OA.

      더보기

      참고문헌 (Reference)

      1 Meulenbelt I, "Urinary CTX-II levels are associated with radiographic subtypes of osteoarthritis in hip, knee, hand, and facet joints in subject with familial osteoarthritis at multiple sites: the GARP study" 65 : 360-365, 2006

      2 Manicourt DH, "Treatment with calcitonin suppresses the responses of bone, cartilage, and synovium in the early stages of canine experimental osteoarthritis and significantly reduces the severity of the cartilage lesions" 42 : 1159-1167, 1999

      3 Sellam J, "The role of synovitis in pathophysiology and clinical symptoms of osteoarthritis" 6 : 625-635, 2010

      4 Hayami T, "The role of subchondral bone remodeling in osteoarthritis: reduction of cartilage degeneration and prevention of osteophyte formation by alendronate in the rat anterior cruciate ligament transection model" 50 : 1193-1206, 2004

      5 Lotz M, "The role of nitric oxide in articular cartilage damage" 25 : 269-282, 1999

      6 Fernandes JC, "The role of cytokines in osteoarthritis pathophysiology" 39 : 237-246, 2002

      7 Karsdal MA, "The effect of oral salmon calcitonin delivered with 5-CNAC on bone and cartilage degradation in osteoarthritic patients: a 14-day randomized study" 18 : 150-159, 2010

      8 Sondergaard BC, "The effect of oral calcitonin on cartilage turnover and surface erosion in an ovariectomized rat model" 56 : 2674-2678, 2007

      9 Ofluoglu D, "The effect of calcitonin on beta- endorphin levels in postmenopausal osteoporotic patients with back pain" 26 : 44-49, 2007

      10 Karsdal MA, "Should subchondral bone turnover be targeted when treating osteoarthritis?" 16 : 638-646, 2008

      1 Meulenbelt I, "Urinary CTX-II levels are associated with radiographic subtypes of osteoarthritis in hip, knee, hand, and facet joints in subject with familial osteoarthritis at multiple sites: the GARP study" 65 : 360-365, 2006

      2 Manicourt DH, "Treatment with calcitonin suppresses the responses of bone, cartilage, and synovium in the early stages of canine experimental osteoarthritis and significantly reduces the severity of the cartilage lesions" 42 : 1159-1167, 1999

      3 Sellam J, "The role of synovitis in pathophysiology and clinical symptoms of osteoarthritis" 6 : 625-635, 2010

      4 Hayami T, "The role of subchondral bone remodeling in osteoarthritis: reduction of cartilage degeneration and prevention of osteophyte formation by alendronate in the rat anterior cruciate ligament transection model" 50 : 1193-1206, 2004

      5 Lotz M, "The role of nitric oxide in articular cartilage damage" 25 : 269-282, 1999

      6 Fernandes JC, "The role of cytokines in osteoarthritis pathophysiology" 39 : 237-246, 2002

      7 Karsdal MA, "The effect of oral salmon calcitonin delivered with 5-CNAC on bone and cartilage degradation in osteoarthritic patients: a 14-day randomized study" 18 : 150-159, 2010

      8 Sondergaard BC, "The effect of oral calcitonin on cartilage turnover and surface erosion in an ovariectomized rat model" 56 : 2674-2678, 2007

      9 Ofluoglu D, "The effect of calcitonin on beta- endorphin levels in postmenopausal osteoporotic patients with back pain" 26 : 44-49, 2007

      10 Karsdal MA, "Should subchondral bone turnover be targeted when treating osteoarthritis?" 16 : 638-646, 2008

      11 Di Nino DL, "Positive regulation of endochondral cartilage growth by perichondrial and periosteal calcitonin" 144 : 1979-1983, 2003

      12 van Baar ME, "Pain and disability in patients with osteoarthritis of hip or knee: the relationship with articular, kinesiological and psychological characteristics" 25 : 125-133, 1998

      13 Lyritis GP, "Pain Relief From Nasal Salmon Calcitonin I . n Osteoporotic Vertebral Crush Fractures" 275 : 112-114, 1997

      14 Manicourt DH, "Oral salmon calcitonin reduces Lequesne’s algofunctional index scores and decreases urinary and serum levels of biomarkers of joint metabolism in knee osteoarthritis" 54 : 3205-3211, 2006

      15 Bagger YZ, "Oral salmon calcitonin induced suppression of urinary collogen type II degradation in postmenapausal women: A new potential treatment of osteoarthritis" 37 : 425-430, 2005

      16 Ito A, "Mechanisms for ovariectomy-induced hyperalgesia and its relief by calcitonin: participation of 5-HT1A-like receptor on C-afferent terminals in substantia gelatinosa of the rat spinal cord" 20 : 6302-6308, 2000

      17 Sondergaard BC, "Investigation of the direct effects of salmon calcitonin on human osteoarthritic chondrocytes" 11 : 62-, 2010

      18 Dam EB, "Increased urinary excretion of C-telopeptides of type II collagen (CTX-II) predicts cartilage loss over 21 months by MRI" 17 : 384-389, 2009

      19 Petrella RJ, "Home based exercise therapy for older patients with knee osteoarthritis: a randomized clinical trial" 27 : 2215-2221, 2000

      20 Franchimont P, "Effects of human and salmon calcitonin on human articular chondrocytes cultivated in clusters" 69 : 259-266, 1989

      21 Evcik D, "Effectiveness of a home-based exercise therapy and walking program on osteoarthritis of the knee" 22 : 103-106, 2002

      22 Badurski J, "Comparative analysis of three treatment regimens for treating gonarthritis with calcitonin, naproxen and flavonoids based on EULAR criteria and visual analogue scale (VAS)" 50 : 37-40, 1995

      23 Meulenbelt I, "Clusters of biochemical markers are associated with radiographic subtypes of osteoarthritis (OA) in subject with familial OA at multiple sites. The GARP study" 15 : 379-385, 2007

      24 Suzuki H, "Calcitonin-induced changes in the cytoskeleton are mediated by a signal pathway associated with protein kinase A in osteoclasts" 137 : 4685-4690, 1996

      25 Karsdal MA, "Calcitonin is involved in cartilage homeostasis: is calcitonin a treatment for OA?" 14 : 617-624, 2006

      26 Shyu JF, "Calcitonin induces podosome disassembly and detachment of osteoclasts by modulating Pyk2 and Src activities" 40 : 1329-1342, 2007

      27 Sondergaard BC, "Calcitonin directly attenuates collagen type II degradation by inhibition of matrix metalloproteinase expression and activity in articular chondrocytes" 14 : 759-768, 2006

      28 Takayama B, "An immunohistochemical study of the antinociceptive effect of calcitonin in ovariectomized rats" 9 : 164-, 2008

      29 Bredella MA, "Accuracy of T2-weighted fast spinecho MR imaging with fat saturation in detecting cartilage defects in the knee: comparison with arthroscopy in 130 patients" 172 : 1073-1080, 1999

      30 Reijman M, "A new marker for osteoarthritis: cross-sectional and longitudinal approach" 50 : 2471-2478, 2004

      더보기

      동일학술지(권/호) 다른 논문

      분석정보

      View

      상세정보조회

      0

      Usage

      원문다운로드

      0

      대출신청

      0

      복사신청

      0

      EDDS신청

      0

      동일 주제 내 활용도 TOP

      더보기

      주제

      연도별 연구동향

      연도별 활용동향

      연관논문

      연구자 네트워크맵

      공동연구자 (7)

      유사연구자 (20) 활용도상위20명

      인용정보 인용지수 설명보기

      학술지 이력

      학술지 이력
      연월일 이력구분 이력상세 등재구분
      2023 평가예정 해외DB학술지평가 신청대상 (해외등재 학술지 평가)
      2020-01-01 평가 등재학술지 유지 (해외등재 학술지 평가) KCI등재
      2011-01-01 평가 등재학술지 유지 (등재유지) KCI등재
      2009-01-01 평가 등재학술지 유지 (등재유지) KCI등재
      2005-01-01 평가 SCI 등재 (등재유지) KCI등재
      2002-01-01 평가 등재학술지 선정 (등재후보2차) KCI등재
      1999-07-01 평가 등재후보학술지 선정 (신규평가) KCI등재후보
      더보기

      학술지 인용정보

      학술지 인용정보
      기준연도 WOS-KCI 통합IF(2년) KCIF(2년) KCIF(3년)
      2016 1.48 0.37 1.06
      KCIF(4년) KCIF(5년) 중심성지수(3년) 즉시성지수
      0.85 0.75 0.691 0.11
      더보기

      이 자료와 함께 이용한 RISS 자료

      나만을 위한 추천자료

      해외이동버튼